We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · November 20, 2019

Improved Glycemic Variability and Time in Range With Dapagliflozin vs Gliclazide Modified-Release Among Adults With Type 2 Diabetes Evaluated by CGM

Diabetes, Obesity & Metabolism

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Improved Glycemic Variability and Time in Range With Dapagliflozin Versus Gliclazide Modified Release Among Adults With Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12-week Randomized Controlled Trial
Diabetes Obes Metab 2019 Nov 10;[EPub Ahead of Print], AGD Vianna, CS Lacerda, LM Pechmann, MG Polesel, EC Marino, M Scharf, JM Detsch, K Marques, CP Sanches

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading